PAYS — PaySign, Inc.

Summary of Paysign Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Increased by 40.5% to $82 million for the full year.
• Net Income: Rose 98% to $7.6 million.
• Adjusted EBITDA: Grew 107% to $19.9 million.
• Operating Margins: Improved by 723 basis points to 9% from 1.7% in the previous year.
• Patient Affordability Revenue: Increased 168% year-over-year to $33.9 million.
• Plasma Donor Compensation Revenue: Grew 4% to $45.6 million.
• Cash Position: Ended the year with $21.1 million in cash, nearly double from the prior year.

2. Strategic Updates and Business Highlights

• The patient affordability business is a key growth driver, processing claims increased by approximately 79%.
• Successfully added 55 new patient affordability programs, totaling 131 active programs.
• The platform delivered nearly $1 billion in financial assistance to over 840,000 patients.
• Dynamic business rules technology saved clients over $325 million in 2025.
• The plasma business is expected to continue growing, primarily through increased efficiency at existing centers rather than new openings.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $106.5 million and $110.5 million, representing 30% to 35% year-over-year growth.
• Operating Margins: Expected to expand further, with gross profit margins projected between 60% to 62%.
• Net Income: Anticipated to nearly double, reaching $13 million to $16 million.
• Q1 2026 Revenue: Forecasted at $27 million to $27.5 million, reflecting a 45.2% to 47.8% growth over Q1 2025.

4. Bad News, Challenges, or Points of Concern

• Concerns were raised about potential headwinds from legislative and regulatory changes affecting co-pay programs, although management does not see these as immediate threats.
• The plasma business faced a decline in average donations per center due to elevated inventory levels.
• There is a competitive landscape with emerging players, but management believes their technology and operational advantages will sustain their market position.

5. Notable Q&A Insights

• Management indicated no slowdown in demand from pharmaceutical manufacturers, countering industry concerns.
• There is ongoing interest in GLP-1 drugs, but current offerings do not include major weight-loss products.
• The company is focused on enhancing its dynamic business rules and integrating AI to improve operational efficiency.
• Investors expressed concerns about the market's understanding of the co-pay business model, with management acknowledging the need for clearer communication regarding their unique value proposition.
• The competitive landscape is evolving, but Paysign's innovative approach and technology are seen as significant advantages.

Overall, Paysign demonstrated strong growth in 2025, with a robust outlook for 2026 driven by its patient affordability business, while also navigating challenges in the plasma sector and competitive pressures.